London: The European Medicines AgencyThe U.S.’s chief vaccine expert said he was not concerned by the recent figures New York State on the decline of security from pfizer and BioNTech SE COVID-19 vaccine in children aged 5 to 11 years.
“This study somehow showed less protection from symptomatic COVID-19, but it’s still within the level of protection we’re seeing with the vaccines that we have.” omicron And after a primary series,” EMA’s Head of Vaccine Strategy, marco cavalryAdding to the regulator, the data will be assessed in more detail, he said at a media briefing.
“We would not be particularly concerned at this stage with respect to these results,” he said.
US researchers said this week that two doses of the vaccine were protective against severe disease in children during the recent Omicron type boom, but it quickly lost most of its ability to prevent infection in the age group.
“This study somehow showed less protection from symptomatic COVID-19, but it’s still within the level of protection we’re seeing with the vaccines that we have.” omicron And after a primary series,” EMA’s Head of Vaccine Strategy, marco cavalryAdding to the regulator, the data will be assessed in more detail, he said at a media briefing.
“We would not be particularly concerned at this stage with respect to these results,” he said.
US researchers said this week that two doses of the vaccine were protective against severe disease in children during the recent Omicron type boom, but it quickly lost most of its ability to prevent infection in the age group.